Aberdeen Group plc Reduces Stock Holdings in Moderna, Inc. $MRNA

Aberdeen Group plc lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 76.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,225 shares of the company’s stock after selling 62,274 shares during the quarter. Aberdeen Group plc’s holdings in Moderna were worth $497,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Rothschild Investment LLC increased its holdings in Moderna by 94.1% during the 2nd quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock valued at $25,000 after acquiring an additional 446 shares in the last quarter. Atlantic Union Bankshares Corp acquired a new stake in shares of Moderna in the second quarter valued at approximately $26,000. MUFG Securities EMEA plc acquired a new stake in shares of Moderna in the second quarter valued at approximately $28,000. Assetmark Inc. increased its stake in shares of Moderna by 137.7% during the 2nd quarter. Assetmark Inc. now owns 1,298 shares of the company’s stock worth $36,000 after purchasing an additional 752 shares in the last quarter. Finally, EverSource Wealth Advisors LLC raised its position in shares of Moderna by 148.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock worth $37,000 after purchasing an additional 801 shares during the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Up 0.3%

MRNA stock opened at $49.87 on Monday. The company has a market cap of $19.49 billion, a price-to-earnings ratio of -6.86 and a beta of 1.31. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07. The business has a fifty day simple moving average of $39.02 and a 200-day simple moving average of $30.49. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $55.20.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.79) by $0.68. The firm had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The firm’s revenue for the quarter was down 33.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.91) earnings per share. On average, equities research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Insider Buying and Selling at Moderna

In other news, Director Noubar Afeyan sold 23,853 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director owned 3,924 shares in the company, valued at approximately $115,679.52. The trade was a 85.87% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 10.90% of the stock is owned by corporate insiders.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA will review Moderna’s mRNA flu vaccine application after an initial refusal-to-file, with regulators now targeting a decision by Aug. 5, 2026 — a reversal that boosts the commercial outlook for a new recurring vaccine market and spurred an earlier jump in the stock. Moderna Stock Jumps After FDA Reverses Course on Flu Shot
• Positive Sentiment: Goldman Sachs analyst flagged upside for MRNA, an institutional vote of confidence that can support sentiment and buying interest. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna will present at TD Cowen and Barclays healthcare conferences in March — routine investor access that may provide more management detail but is unlikely by itself to move the stock dramatically. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech sued Moderna in Delaware federal court alleging Moderna’s mNexspike infringes a patent tied to BioNTech/Pfizer’s Comirnaty—new litigation increases legal risk, potential damages or injunctions, and heightens competitive/legal uncertainty for Moderna’s COVID-19/respiratory vaccine portfolio. BioNTech sues Moderna for patent infringement over COVID-19 shots
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in its patent dispute with Arbutus, representing another legal setback that could increase exposure and costs from long-running mRNA technology litigation. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Morgan Stanley set a $30.00 target price on Moderna in a research note on Monday, February 16th. TD Cowen restated a “hold” rating on shares of Moderna in a research report on Thursday, January 29th. Wall Street Zen raised Moderna from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Piper Sandler reissued an “overweight” rating on shares of Moderna in a research note on Monday, December 1st. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating and set a $45.00 price target on shares of Moderna in a research note on Tuesday, February 17th. Two analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $31.47.

About Moderna

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.